Tevogen Bio Holdings INC Form 4 insider transactions

Victor J. Sordillo, a Director at Tevogen Bio Holdings Inc., was granted 40,000 shares of common stock under the company's 2024 Omnibus Incentive Plan.

Tevogen Bio Holdings Inc. reports a significant stock grant to CEO Ryan H. Saadi, comprising 1.22 million restricted shares vesting over four years.

Tevogen Bio Holdings Inc. reports a stock grant to Director Susan M. Podlogar, with vesting tied to significant revenue milestones.

Tevogen Bio Holdings Inc. reports a restricted stock grant to Director Curtis L. Patton, with vesting tied to revenue milestones.

Tevogen Bio Holdings Inc. reports a restricted stock grant to Director Goh Keow Lin, with vesting tied to revenue milestones and continued service.

Tevogen Bio Holdings Inc. reports a restricted stock grant to Director Feike Jeffrey L., with vesting tied to significant revenue milestones.

Tevogen Bio Holdings Inc. reports a restricted stock grant to its Chief Financial Officer, Kirti Desai, with vesting tied to significant revenue milestones.

Tevogen Bio's Chief Scientific Officer, Neal Flomenberg, sold common stock to cover tax liabilities from restricted stock unit vesting.

Tevogen Bio CEO Ryan H. Saadi reported a 50,000-share charitable gift.

Tevogen Bio Holdings Inc. CFO Kirti Desai gifted 300,000 shares of common stock to two charitable organizations.

Tevogen Bio Holdings Inc. CEO Ryan H. Saadi reported gifting 460,000 shares of common stock to two charitable organizations on December 11, 2025, under a Rule 10b5-1 plan.

Tevogen Bio Holdings Inc. CEO Ryan H. Saadi reported gifting 20,000 shares of common stock to two charitable organizations.

Tevogen Bio Holdings Inc. CEO Ryan H. Saadi was granted 8,000,000 shares of common stock as restricted stock, set to vest in annual installments beginning in 2032.

Tevogen Bio Holdings Inc. has granted 200,000 restricted shares of common stock to Chief Commercial Officer Sadiq Khan, vesting in three equal annual installments starting June 27, 2030.

Tevogen Bio Holdings Inc. has granted 300,000 restricted shares to its Chief Scientific Officer, Neal Flomenberg, as part of its 2024 Omnibus Incentive Plan, with vesting commencing in 2030.

Tevogen Bio Holdings Inc.'s Chief Financial Officer, Kirti Desai, was granted 750,000 shares of common stock as restricted stock, vesting over three years starting in 2030.

Tevogen Bio Holdings Inc. CEO, Director, and 10% Owner Ryan H. Saadi reported the sale of 1,438,206 shares of common stock on June 9, 2025, at a weighted average price of $1.23 per share.

Neal Flomenberg, Chief Scientific Officer of Tevogen Bio Holdings, sold shares to cover tax obligations related to vesting of restricted stock units.

Neal Flomenberg, Chief Scientific Officer of Tevogen Bio Holdings, sold shares of common stock to satisfy tax obligations related to vesting of restricted stock units.

Neal Flomenberg, Chief Scientific Officer of Tevogen Bio Holdings, sold shares of common stock between March 4th and March 6th, 2025, to cover tax obligations related to the vesting of restricted stock units.

A Tevogen Bio Holdings director, Jeffrey L. Feike, was granted 240,000 restricted stock units (RSUs) on December 23, 2024, which will vest over four years.

Director Curtis L. Patton of Tevogen Bio Holdings Inc. was granted 240,000 restricted stock units (RSUs) on December 23, 2024, which will vest over four years.

Director Susan M Podlogar of Tevogen Bio Holdings Inc. was granted 240,000 restricted stock units (RSUs) on December 23, 2024, which will vest over four years.

Victor J. Sordillo, a director at Tevogen Bio Holdings, received 240,000 restricted stock units that vested immediately and another 240,000 that will vest over four years.

Director Goh Keow Lin of Tevogen Bio Holdings Inc. was granted 240,000 restricted stock units (RSUs) that will vest over four years.

Neal Flomenberg, Chief Scientific Officer of Tevogen Bio Holdings, sold shares to cover tax obligations related to vesting of restricted stock units.

Kirti Desai, CFO of Tevogen Bio Holdings Inc., recently purchased 3,000 shares of common stock at $0.82 per share, increasing his total holdings to 9,699,186 shares.

CEO Ryan H. Saadi reports purchasing additional shares of Tevogen Bio Holdings, increasing his direct holdings.